BioPharm News

Mar 25, 2015
By BioPharm International Editors
Genentech plans to invest more than $125 million in an expansion of its fill/finish facility in Hillsboro, OR.
Mar 25, 2015
FDA has approved another indication for Eylea, a treatment for diabetic retinopathy in patients with diabetic macular edema.
Mar 24, 2015
By BioPharm International Editors
Emergent BioSolutions announced FDA approval of Anthrasil, an inhalable treatment that targets Anthrax toxins, as well as a contract with BARDA to develop NuThrax, an anthrax vaccine candidate.
BioPharm International: Mar 23, 2015
By BioPharm International Editors
The agency provides guidance on determining the need for environmental assessments for gene therapies, vectored vaccines, and viral and microbial products.
BioPharm International: Mar 23, 2015
Clinical trial results suggest that monoclonal antibodies targeting the function of proinflammatory cytokine IL-17A in psoriasis may be significantly superior to other treatments.
BioPharm International: Mar 22, 2015
By BioPharm International Editors
Guidance provides labeling standards and an implementation guide for electronic submission of lot distribution reports.
BioPharm International: Mar 22, 2015
The new 2000-L bioreactor will double Rentschler’s single-use manufacturing capabilities.
BioPharm International: Mar 22, 2015
The company’s new corporate name will simply be Biogen.
BioPharm International: Mar 19, 2015
As a result of the decision, Sandoz will be able to immediately launch Zarxio, the first biosimilar in the United States.
BioPharm International: Mar 19, 2015
Biogen Idec says its investigational candidate is the first drug to both reduce amyloid plaque in the brain and slow cognitive decline.